Obinutuzumab (Intravenous)
Medically reviewed by Drugs.com. Last updated on Mar 23, 2022.
Hepatitis B virus (HBV) reactivation can occur in patients receiving obinutuzumab or other CD20-directed cytolytic antibodies, which can progress to life-threatening or fatal fulminant hepatitis or hepatic failure. Screen patients at baseline for HBV infection. Monitor HBV-positive patients during and after treatment with obinutuzumab. If HBV reactivation occurs, discontinue obinutuzumab and concomitant medications. Life-threatening or fatal progressive multifocal leukoencephalopathy has also been reported .
Commonly used brand name(s)
In the U.S.
- Gazyva
Available Dosage Forms:
- Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Monoclonal Antibody
Uses for obinutuzumab
Obinutuzumab injection is used together with other medicines (eg, chlorambucil) to treat chronic lymphocytic leukemia (CLL).
Obinutuzumab injection is also used together with bendamustine to treat follicular lymphoma after other medicines (eg, rituximab) did not work well. It is also used to treat patients who previously had untreated stage II bulky, III or IV follicular lymphoma and are at least having partial temporary recovery (remission) from their cancer. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Obinutuzumab is an antineoplastic agent (cancer medicine).
Obinutuzumab is to be given only by or under the direct supervision of your doctor.
Before using obinutuzumab
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For obinutuzumab, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to obinutuzumab or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of obinutuzumab injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of obinutuzumab injection in the elderly.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Interactions with food/tobacco/alcohol
Certain medicines should not be used at or around the time of eating food or eating certain ty..
